HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection - PubMed (original) (raw)
. 1993 May 15;150(10):4659-71.
Affiliations
- PMID: 7683326
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection
R Nayersina et al. J Immunol. 1993.
Abstract
Inasmuch as the hepatitis B virus (HBV) is not directly cytopathic for the infected hepatocyte, it is generally presumed that viral clearance and liver cell injury during viral hepatitis are due to a CTL response to HBV encoded Ag presented by HLA class I molecules. We have previously examined the peripheral blood CTL response to two HBV nucleocapsid epitopes in patients with acute and chronic viral hepatitis, one of which is restricted by HLA-A2, whereas the other is dually restricted by HLA-A31 and Aw68. In this study, we defined the HLA-A2-restricted CTL response to the hepatitis B surface Ag (HBsAg) by using a panel of HBsAg-derived synthetic peptides containing the ideal HLA-A2.1 binding motif (-L------V). Several novel aspects of HBV immunobiology and pathogenesis are evident from this study. First, the peripheral blood CTL response to HBV-encoded Ag is remarkably polyclonal and multispecific in most patients with acute hepatitis. Indeed, HLA-A2-restricted CTL specific for as many as four envelope epitopes and one nucleocapsid epitope were found to be present simultaneously in individual patients with acute viral hepatitis. Second, HBV-specific CTL are not detectable in the peripheral blood in a minority of patients with acute hepatitis, nor have we detected a CTL response in any of the patients with chronic hepatitis that we have studied thus far. Although the cellular and molecular basis for CTL nonresponse remains to be determined, the data suggest that it may contribute to viral persistence. Third, the diversity and the specificity of the CTL response is determined in part by the coding sequence of the viral genome present in each infected patient. Indeed, the apparent nonresponse of some acutely infected patients to at least one HBsAg-specific CTL epitope actually reflects infection by a viral variant that contains a critical substitution in one of the anchor residues within the epitope. Finally, at a fundamental level, the data suggest that the presence of the HLA-A2.1-binding motif in a peptide may not be sufficient for binding; and the capacity of a peptide to bind the class I molecule does not guarantee that it will be immunogenic.
Similar articles
- HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.
Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, Ferrari C, Chisari FV. Missale G, et al. J Exp Med. 1993 Mar 1;177(3):751-62. doi: 10.1084/jem.177.3.751. J Exp Med. 1993. PMID: 7679709 Free PMC article. - Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor.
Bertoletti A, Southwood S, Chesnut R, Sette A, Falco M, Ferrara GB, Penna A, Boni C, Fiaccadori F, Ferrari C. Bertoletti A, et al. Hepatology. 1997 Oct;26(4):1027-34. doi: 10.1002/hep.510260435. Hepatology. 1997. PMID: 9328331 - Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope.
Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, Giuberti T, Fiaccadori F, Ferrari C. Bertoletti A, et al. J Exp Med. 1994 Sep 1;180(3):933-43. doi: 10.1084/jem.180.3.933. J Exp Med. 1994. PMID: 7520476 Free PMC article. - Hepatitis B virus immunopathogenesis.
Chisari FV, Ferrari C. Chisari FV, et al. Annu Rev Immunol. 1995;13:29-60. doi: 10.1146/annurev.iy.13.040195.000333. Annu Rev Immunol. 1995. PMID: 7612225 Review. - Immunological aspects of hepatitis B virus infection.
Edgington TS, Chisari FV. Edgington TS, et al. Am J Med Sci. 1975 Sep-Oct;270(2):212-27. Am J Med Sci. 1975. PMID: 799469 Review.
Cited by
- Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes.
Ding Y, Zhou Z, Li X, Zhao C, Jin X, Liu X, Wu Y, Mei X, Li J, Qiu J, Shen C. Ding Y, et al. Front Immunol. 2022 Apr 7;13:847105. doi: 10.3389/fimmu.2022.847105. eCollection 2022. Front Immunol. 2022. PMID: 35464415 Free PMC article. - CD4+ T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy.
Buschow SI, Jansen DTSL. Buschow SI, et al. Cells. 2021 May 6;10(5):1114. doi: 10.3390/cells10051114. Cells. 2021. PMID: 34066322 Free PMC article. Review. - Therapeutic vaccination for treatment of chronic hepatitis B.
Cargill T, Barnes E. Cargill T, et al. Clin Exp Immunol. 2021 Aug;205(2):106-118. doi: 10.1111/cei.13614. Epub 2021 Jun 8. Clin Exp Immunol. 2021. PMID: 33969474 Free PMC article. Review. - Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
Zhu L, Yang X, Zhong D, Xie S, Shi W, Li Y, Hou X, HuaYao, Zhou H, Zhao M, Ding Z, Zhao X, Mo F, Yin S, Liu A, Lu X. Zhu L, et al. J Immunol Res. 2020 Sep 7;2020:2454907. doi: 10.1155/2020/2454907. eCollection 2020. J Immunol Res. 2020. PMID: 32964055 Free PMC article. Review. - Targeting cancers through TCR-peptide/MHC interactions.
He Q, Jiang X, Zhou X, Weng J. He Q, et al. J Hematol Oncol. 2019 Dec 18;12(1):139. doi: 10.1186/s13045-019-0812-8. J Hematol Oncol. 2019. PMID: 31852498 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials